Sociedad Química y Minera de Chile S.A.

NYSE:SQM Stock Report

Market Cap: US$12.2b

Sociedad Química y Minera de Chile Valuation

Is SQM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SQM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SQM ($42.43) is trading below our estimate of fair value ($176.26)

Significantly Below Fair Value: SQM is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SQM?

Other financial metrics that can be useful for relative valuation.

SQM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.6x
Enterprise Value/EBITDA7.4x
PEG Ratio9.1x

Price to Sales Ratio vs Peers

How does SQM's PS Ratio compare to its peers?

The above table shows the PS ratio for SQM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
ALB Albemarle
1.6x6.0%US$12.3b
CE Celanese
1.3x3.7%US$14.8b
EMN Eastman Chemical
1.4x3.9%US$12.8b
RPM RPM International
2.3x3.0%US$16.6b
SQM Sociedad Química y Minera de Chile
2.2x9.2%US$12.2b

Price-To-Sales vs Peers: SQM is expensive based on its Price-To-Sales Ratio (2.2x) compared to the peer average (1.6x).


Price to Earnings Ratio vs Industry

How does SQM's PE Ratio compare vs other companies in the US Chemicals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SQM is expensive based on its Price-To-Sales Ratio (2.2x) compared to the US Chemicals industry average (1.4x).


Price to Sales Ratio vs Fair Ratio

What is SQM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SQM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.2x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: SQM is good value based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SQM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$42.43
US$56.69
+33.6%
26.7%US$85.00US$32.00n/a17
Oct ’25US$41.42
US$56.69
+36.9%
26.7%US$85.00US$32.00n/a17
Sep ’25US$38.80
US$56.86
+46.6%
26.2%US$85.00US$35.00n/a17
Aug ’25US$36.63
US$60.98
+66.5%
26.7%US$95.00US$35.00n/a18
Jul ’25US$40.37
US$65.75
+62.9%
21.1%US$95.00US$45.00n/a16
Jun ’25US$46.70
US$66.81
+43.1%
21.9%US$95.00US$45.00n/a16
May ’25US$45.83
US$67.10
+46.4%
22.1%US$95.00US$42.00n/a17
Apr ’25US$48.99
US$68.55
+39.9%
21.5%US$95.00US$46.00n/a18
Mar ’25US$51.43
US$68.69
+33.6%
23.4%US$95.00US$46.00n/a17
Feb ’25US$42.16
US$72.21
+71.3%
20.7%US$95.00US$46.00n/a18
Jan ’25US$60.22
US$75.27
+25.0%
17.4%US$95.00US$52.00n/a17
Dec ’24US$54.00
US$80.34
+48.8%
24.2%US$136.00US$52.00n/a17
Nov ’24US$47.47
US$82.22
+73.2%
22.2%US$136.00US$58.00n/a17
Oct ’24US$59.67
US$87.11
+46.0%
18.9%US$136.00US$62.80US$41.4217
Sep ’24US$63.20
US$87.24
+38.0%
19.4%US$136.00US$62.80US$38.8016
Aug ’24US$72.07
US$90.65
+25.8%
17.3%US$136.00US$67.90US$36.6316
Jul ’24US$72.62
US$92.85
+27.9%
21.1%US$136.00US$60.60US$40.3716
Jun ’24US$66.17
US$96.04
+45.1%
21.1%US$136.00US$60.60US$46.7017
May ’24US$64.84
US$100.44
+54.9%
19.7%US$136.00US$73.00US$45.8316
Apr ’24US$81.06
US$113.06
+39.5%
16.5%US$145.00US$80.00US$48.9916
Mar ’24US$88.16
US$112.75
+27.9%
17.1%US$145.00US$80.00US$51.4316
Feb ’24US$96.60
US$112.75
+16.7%
17.1%US$145.00US$80.00US$42.1616
Jan ’24US$79.84
US$115.38
+44.5%
15.7%US$145.00US$80.00US$60.2216
Dec ’23US$97.12
US$116.75
+20.2%
14.8%US$141.00US$80.00US$54.0016
Nov ’23US$93.76
US$116.06
+23.8%
14.1%US$140.00US$80.00US$47.4716
Oct ’23US$90.75
US$116.06
+27.9%
14.1%US$140.00US$80.00US$59.6716

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies